In the FALCON study of CA4P in combination with CP–bevacizumab in patients with NSCLC, all-grade HTN was increased in the CP–bevacizumab–CA4P arm relative to the CP–bevacizumab arm (55% vs 45%) [16]. Here, CP is linked to hypertensive disorder.